Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Citrate clearance
研究概览
简要总结
Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).
详细描述
This study aimed to evaluate citrate PKs, metabolic complications, and clinical outcomes among critically ill acute liver failure (ALF) and acute on top chronic liver failure (ACLF) patients receiving CRRT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Critically ill ALF or ACLF adult patients with AKI
- •aged ≥ 18 y old
- •Currently receiving CRRT.
排除标准
- •severe acidosis (pH < 7.1) or severe alkalosis (pH > 7.55)
- •blood transfusion within 24 h prior to the study
- •use of citrate-containing medications
- •severe hypocalcemia (serum ionized calcium < 0.8 mmol/L)
- •use of heparin as anticoagulation
研究组 & 干预措施
Acute Liver Failure
Acute liver failure critically ill patients receiving CRRT
干预措施: Pharmacokinetic study (Diagnostic Test)
Acute on top Chronic Liver Failure
Acute on top chronic liver failure critically ill patients receiving CRRT
干预措施: Pharmacokinetic study (Diagnostic Test)
结局指标
主要结局
Citrate clearance
时间窗: 4 hours
Citrate clearance by body
次要结局
- Change of ionized magnesium(4 hours)
- Change of bicarbonate(4 hours)
- Tmax(2 hours)
- Area under the time curve(4 hours)
- Citrate accumulation(4 hours)
- Change of systemic ionized calcium(4 hours)
- Ratio of total calcium to systemic ionized calcium(4 hours)
研究者
Nattachai Srisawat ,M.D.
Director of Excellence Center for Critical Care Nephrology
Chulalongkorn University